WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, Inc., one of
the world's leading research and advisory firms focusing on pharmaceutical and
health care issues, finds that although more-expensive atypical antipsychotics
such as Eli Lilly's Zyprexa, Otsuka Pharmaceutical/Bristol-Myers Squibb's
Abilify, Janssen's Risperdal, AstraZeneca's Seroquel, and Pfizer's Geodon will
drive the schizophrenia drug market during the period 2003-2013, they will
face generic competition by the end of this time frame. According to a new
Pharmacor study entitled Schizophrenia, generic erosion will exact a heavy
toll on the market because these antipsychotics lose patent protection in 2007
"Generics will have the greatest impact on the U.S. market, which is the
largest and most receptive market for generics," said Michelle Grady, analyst
at Decision Resources. "This market will experience a 3.0% annual decline over
the period 2008-2013. The launch of depot formulations of atypical
antipsychotics and a few other less promising emerging agents will be the only
protection against a more precipitous decline."
Virtually all patients require drug therapy to cope with the symptoms of
schizophrenia, but as many as 30% of schizophrenia patients are refractory to
available drugs. Furthermore, although most physicians agree that current drug
therapy adequately addresses the positive symptoms of schizophrenia, these
same drugs do not adequately treat the negative symptoms and cognitive
dysfunction associated with schizophrenia.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market-
impacting factors and analyzes the commercial outlook for drugs in research
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com) is a world
leader in research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their chosen
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources, Inc.